Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play.

Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Radiology (Impact Factor: 6.21). 05/2012; 263(2):344-61. DOI: 10.1148/radiol.12110433
Source: PubMed

ABSTRACT Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy coupled with the absence of any approved disease-modifying therapies at present position AD as a dominant public health problem. Major advances have occurred in the development of disease biomarkers for AD in the past 2 decades. At present, the most well-developed AD biomarkers are the cerebrospinal fluid analytes amyloid-β 42 and tau and the brain imaging measures amyloid positron emission tomography (PET), fluorodeoxyglucose PET, and magnetic resonance imaging. CSF and imaging biomarkers are incorporated into revised diagnostic guidelines for AD, which have recently been updated for the first time since their original formulation in 1984. Results of recent studies suggest the possibility of an ordered evolution of AD biomarker abnormalities that can be used to stage the typical 20-30-year course of the disease. When compared with biomarkers in other areas of medicine, however, the absence of standardized quantitative metrics for AD imaging biomarkers constitutes a major deficiency. Failure to move toward a standardized system of quantitative metrics has substantially limited potential diagnostic usefulness of imaging in AD. This presents an important opportunity that, if widely embraced, could greatly expand the application of imaging to improve clinical diagnosis and the quality and efficiency of clinical trials.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mild Cognitive Impairment (MCI) represents a critical point for controlling cognitive decline. Patterns of communication difficulty have been observed in patients with MCI and warrant examination and management. The present systematic review examined (1) characteristics of communication difficulty in MCI by focusing on two domains: expressive and receptive communication, and (2) cognitive interventions that addressed communication difficulties in individuals with MCI. Of the 28 observational studies we reviewed, expressive and receptive communications were generally impaired in individuals with MCI, compared to their healthy counterparts. However, only one of seven interventions effectively improved communication related outcomes. We finished the paper with a discussion about how neuroplasticity influences communication abilities in individuals with MCI to inform the future development of interventions for communication difficulty.
    Topics in Geriatric Rehabilitation 01/2014; 30(1):18-34. · 0.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diffusion weighted imaging (DWI) and dif-fusion tensor imaging (DTI) are noisy submodalities images in magnetic resonance imaging (MRI) and usu-ally have long acquisition time due to repetitions needed to improve the signal noise ratio (SNR). Here we pro-pose and evaluate anisotropic anomalous diffusion (AAD) filter on DTI and DWI to enhance SNR and reduce the need for repetitions. Anisotropic anomalous diffusion filter is an iterative parametric diffusion filter based on anomalous diffusion. Fractional anisotropy (FA) and mean diffusivity (MD) maps were acquired with different repetitions times and processed using AAD filter to investigate optimum q parameter. SNR, RMSE and Full Width at Half Maximum (FWHM) measures were evaluated as image quality metrics. The results show that filtering based on AAD approach can improve DWI and DTI image quality and preserving relevant aspects in images. We conclude that when the AAD is applied on DWI and DTI images maps we can use images with lower acquisition repetitions time and maintain the image quality comparable to higher acqui-sition images.
    XXIV Brazilian Congress on Biomedical Engineering, Uberlândia; 10/2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common form of dementia among older persons. Pathognomonic hallmarks of the disease include the development of amyloid senile plaques and deposits of neurofibrillary tangles. These changes occur in the brain long before the clinical manifestations of AD (cognitive impairment in particular) become apparent. Nicotinic acetylcholine receptors (AChRs), particularly the α7 subtype, are highly expressed in brain regions relevant to cognitive and memory functions and involved in the processing of sensory information. There is strong evidence that implicates the participation of AChRs in AD. This review briefly introduces current strategies addressing the pathophysiologic findings (amyloid-β-peptide plaques, neurofibrillary tangles) and then focuses on more recent efforts of pharmacologic intervention in AD, specifically targeted to the α7 AChR. Whereas cholinesterase inhibitors such as donepezil, galantamine, or rivastigmine, together with the non-competitive N-methyl-D-aspartate receptor antagonist memantine are at the forefront of present-day clinical intervention for AD, new insights into AChR molecular pharmacology are bringing other drugs, directed at AChRs, to center stage. Among these are the positive allosteric modulators that selectively target α7 AChRs and are aimed at unleashing the factors that hinder agonist-mediated, α7 AChR channel activation. This calls for more detailed knowledge of the distribution, functional properties, and involvement of AChRs in various signaling cascades-together with the corresponding abnormalities in all these properties-to be able to engineer strategies in drug design and evaluate the therapeutic possibilities of new compounds targeting this class of neurotransmitter receptors.
    CNS Drugs 09/2014; · 4.38 Impact Factor